HFS
BTAI icon

Hantz Financial Services’s BioXcel Therapeutics BTAI Stock Holding History

Hantz Financial Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed – – 1709
2024
Q4 		$0 Hold
3
– – ﹤0.01% 1102
2024
Q3 		$0 Hold
3
– – ﹤0.01% 1080
2024
Q2 		$0 Hold
3
– – ﹤0.01% 1077
2024
Q1 		$0 Hold
3
– – ﹤0.01% 1201
2023
Q4 		$0 Hold
3
– – ﹤0.01% 1131
2023
Q3 		$0 Sell
3
-1
-25% -$101 ﹤0.01% 1119
2023
Q2 		$0 Buy
4
+1
+33% +$333 ﹤0.01% 1087
2023
Q1 		$1K Hold
3
– – ﹤0.01% 1040
2022
Q4 		$1K Hold
3
– – ﹤0.01% 1005
2022
Q3 		$1K Hold
3
– – ﹤0.01% 1004
2022
Q2 		$1K Hold
3
– – ﹤0.01% 980
2022
Q1 		$1K Buy
+3
New +$870 ﹤0.01% 981

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Hantz Financial Services's BTAI Position: Q1 2025 in Review

Hantz Financial Services sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 3 shares.

Hantz Financial Services first reported a position in BTAI in Q1 2022 and held it in 12 quarters. The position peaked at $1K in Q1 2023. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Hantz Financial Services reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hantz Financial Services sold 3 BioXcel Therapeutics shares in Q1 2025.
  • Hantz Financial Services first reported a position in BioXcel Therapeutics in Q1 2022 and held it in 12 quarters.
  • Hantz Financial Services's BioXcel Therapeutics position peaked at $1K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Hantz Financial Services's 13F filing for Q1 2025, filed 12 May 2025.